Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

Abstract Number: 1764 • ACR Convergence 2025
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Naomi Patel¹, Aaron Wu², Eli Miloslavsky³, Peter Merkel⁴, John Stone⁵, Hyon K. Choi⁶, Zachary Wallace³ and Emily Hyle², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Evaluating the effectiveness and safety profile of treatment strategies for the induction of remission of individuals with newly diagnosed AAV is important for guiding…
Abstract Number: 1609 • ACR Convergence 2025
A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis
Ravi Kumar U¹, Anoop Chitrabhanu², Ramya Janardana³, Avinash Jain⁴, Nitty Mathews⁵, Rutvi Dave⁵, Prabhu Vasantha Kumar⁶, ashish mathew⁵, john mathew⁵, Prasanna Samuel⁵, Arul Rajamurugan², Vineeta Shobha³ and ruchika goel⁵, ¹Christian Medical college, Vellore, India, Bengaluru, Karnataka, India, ²Madras Medical College, Chennai, India, Chennai, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, Karnataka, India, ⁴SMS Medical College and Hospital, Jaipur, India, JAIPUR, Rajasthan, India, ⁵Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ⁶Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India
Background/Purpose: Rituximab (RTX) has been shown to achieve high remission-induction and sustained maintenance rates across multiple studies and clinical trials in patients with AAV. The…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 1606 • ACR Convergence 2025
One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Naomi Patel¹, Andrew King², Madison Negron³, Zachary Williams⁴, Ana Fernandes¹, Nora Shepherd², Colebrooke Johnson¹, Guy Katz¹, Belen Arevalo Molina¹, Elizabeth Ibiloye⁵, Sam Oh⁶, Zachary Wallace⁷ and Sebastian H Unizony⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Harvard Extension School, Medford, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, South San Francisco, CA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Avacopan has been approved for adjunctive use in adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the US. Here…
Abstract Number: 1598 • ACR Convergence 2025
Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
caterina ricordi¹, elena treppo², Pavel Novikov³, Paul Russo⁴, Luca moroni⁵, Angelo Fassio⁶, Paolo Delvino⁷, hervé lobbes⁸, Chiara Marvisi¹, Francesco Muratore¹, Xavier Puéchal⁹, Carlo Salvarani¹ and Benjamin Terrier¹⁰, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Sechenov University, Moscow, Russia, ⁴Royal Adelaide Hospital, Clinical Immunology and Allergy, Adelaide, Australia, ⁵IRCCS San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, ⁶University of Verona, Department of Medicine, Unit of Rheumatology, Verona, Italy, ⁷University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁸Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: Medium- and small-vessel vasculitides (MVV and SVV) are a heterogeneous group of inflammatory diseases affecting the vascular wall. Current treatment strategies are based on…
Abstract Number: 1596 • ACR Convergence 2025
GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
Brendan Denvir¹, Alexander Hillel², Ami Shah³, Ji Soo Kim¹, Philip Seo² and Brendan Antiochos⁴, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins, CLARKSVILLE, MD
Background/Purpose: Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis that affects all levels of the respiratory tract. Tracheobronchial stenosis (TBS) occurs in…
Abstract Number: 1595 • ACR Convergence 2025
Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
Brendan Denvir¹, Brendan Antiochos², Philip Seo³ and Alexander Hillel³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins, CLARKSVILLE, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Subglottic stenosis (SGS) is a recognized manifestation of granulomatosis with polyangiitis (GPA), occurring in 8–23% of patients. A distinct variant, identified in this study,…
Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Mats Junek¹, Sara Choi², Stephanie Garner³, Saara Rawn⁴, David Cuthbertson⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Ulrich Specks¹³, Kenneth Warrington¹³, Gerard Cox¹, Nader Khalidi¹⁴ and Peter Merkel⁸, ¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴NOSM School of Medicine, Sudbury, ON, Canada, ⁵University of South Florida, Tampa, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴McMaster University, Hamilton, ON, Canada
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Hanna Lindberg¹, Klytaimnistra Voudouri¹, Lars Lindhagen¹, Maria K Svensson², Ann Knight¹ and Johanna Dahlqvist³, ¹Uppsala University, Uppsala, Sweden, ²Uppsala University, Uppsala, ³Uppsala University Hospital, Uppsala, Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…
Abstract Number: 0713 • ACR Convergence 2025
Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Adil Vural¹, Chao Zhang², Yaseen Kinanah¹, Cassandra Calabrese³ and Adam Brown⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH, ⁴Cleveland Clinic, Shaker Heights, OH
Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
Abstract Number: 0726 • ACR Convergence 2025
Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
Sebastian E Sattui¹, Elizabeth Ibiloye², Niranjan Kathe³, Sam Oh⁴, Virginia Noxon-Wood⁵, Iman Mohammadi⁵, Laura Moore-Schiltz⁵ and Tingting Li⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, San Diego, CA, ⁴Amgen Inc, South San Francisco, CA, ⁵Inovalon, Bowie, MD, ⁶Washington University School of Medicine, St. Louis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most common types of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Treatment-related toxicities, particularly from glucocorticoid…
Abstract Number: 1766 • ACR Convergence 2025
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
caterina ricordi¹, Maxime Beydon², Johanne Liberatore³, Pascal Cohen⁴, bertrand Dunogue⁵, Camille Mettler⁶, Benjamin Torreau⁷, Luc Mouthon⁵, Xavier Puéchal⁸ and Benjamin Terrier⁹, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, ³Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁶Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, ⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁹Cochin Hospital, Paris, France
Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
Abstract Number: 0697 • ACR Convergence 2024
Association of ANCA-Associated Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a spectrum of autoimmune disorders characterized by necrotizing small-to-medium vessel inflammation and circulating ANCAs. Represented by granulomatosis…
Abstract Number: 0719 • ACR Convergence 2024
Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease
Joanna El Hajj¹, Jennifer Waller¹, Yagni Patel¹, Wendy Bollag¹, Stephanie Baer² and Rachel Elam³, ¹Augusta University, Augusta, GA, ²VA Augusta Healthcare System, Augusta, GA, ³Augusta University, Evans, GA
Background/Purpose: End-stage renal disease (ESRD) secondary to vasculitis is linked to a higher risk of vertebral fractures compared to other causes of ESRD. It remains…
Abstract Number: 0721 • ACR Convergence 2024
Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study
Xavier Puéchal¹, Michele Iudici¹, Elodie Perrodeau², Claire Goulvestre³, Pascal cohen⁴, Alexis Régent¹, Luc Mouthon⁵, Loïc Guillevin⁴, Raphael Porcher⁶ and Benjamin Terrier⁷, ¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²Hôtel-Dieu, Paris, France, ³Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a frequently relapsing disease for which a meta-analysis concluded that an increase or persistence of ANCA during remission is only…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].